A shortage of estrogen patches is creating challenges for patients who rely on hormone therapy to manage menopause symptoms. The supply disruption has prompted concerns among healthcare providers and patients about continuity of care and symptom control.

According to CNN, the shortage affects certain transdermal estrogen products commonly prescribed to ease hot flashes, night sweats and other menopause-related effects. Pharmacies in multiple regions have reported limited inventory, leading some patients to search for alternative formulations or adjust treatment plans.

Estrogen patches are often favored because they deliver hormones steadily through the skin and may carry different risk profiles compared to oral medications. When supply tightens, physicians may need to consider switching patients to pills, gels or other delivery systems, depending on medical history and tolerance.

Medical experts emphasize that patients should not abruptly stop hormone therapy without consulting a healthcare professional. Sudden changes can result in the return or worsening of symptoms, and individualized guidance is important to maintain safety and effectiveness.

The shortage underscores broader vulnerabilities within pharmaceutical supply chains. As demand for menopause care grows and awareness of hormone therapy increases, ensuring stable access to commonly prescribed treatments has become a pressing issue for both regulators and manufacturers.